This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G47.4 | Special Copayment Reduction: V234 | 5 years |
| B. Synonyms | Narcolepsy and cataplexy |
| C. Adult onset | High likelihood of first onset in adulthood — onset in the teens to 30s is typical, most often in early adulthood (late teens to 20s) |
| 1. History | First described by Gélineau in France in 1880; orexin deficiency identified as the key pathogenesis in 2000 |
| 2. Causes | Autoimmune destruction of hypothalamic orexin (HCRT) neurons causes deficiency with CSF orexin-A <110 pg/mL; strong association with HLA-DQB1*06:02 |
| 3. Genetics | HLA-DQB1*06:02 positivity rate 98%, polygenic predisposition, no single causative gene |
| 4. General epidemiology | Prevalence 20–50/100,000 (Western countries), 160/100,000 in Japan, about 15/100,000 in Korea; age of onset teens to 30s |
| 5. Pathophysiology | Autoimmune destruction of orexin neurons → instability of wake circuits → REM sleep intrusion and cataplexy |
| 6. Symptoms | Four cardinal symptoms: excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations; fragmented nighttime sleep is also common |
| 7. Signs | Emotion-triggered loss of muscle tone, partial cataplexy (facial sagging, knee buckling), automatic behavior, tendency to obesity |
| 8. Screening | Epworth Sleepiness Scale (ESS), HLA-DQB1*06:02 genotyping, sleep diary analysis |
| 9. Diagnosis | Overnight polysomnography (PSG) + Multiple Sleep Latency Test (MSLT), CSF orexin-A measurement, application of ICSD-3-TR criteria |
| 10. Treatment | Modafinil/armodafinil (excessive daytime sleepiness), sodium oxybate (cataplexy and nighttime sleep), pitolisant, solriamfetol; OX2R agonists entering clinical trials |
| 11. Prognosis | Not fatal but lifelong; social functioning can be maintained with appropriate drug treatment; management of obesity and cardiovascular complications is needed |
| 12. Prevention | Prevention of the cause is currently not possible; maintain sleep hygiene, avoid environmental triggers, manage safe driving and work |
| 13. References | Bassetti CL et al. Nat Rev Dis Primers 2019 and 9 other papers |
The history of narcolepsy begins with two clinical papers published in Paris in 1880 by Jean-Baptiste-Édouard Gélineau, a psychiatrist and neurologist from Bordeaux, France. Gélineau observed a patient, a wine merchant, who throughout adulthood suffered from sudden attacks of sleep and loss of muscle tone triggered by emotional stimuli, and was the first to describe this condition as an independent clinical disease, naming it narcolepsie by combining the Greek "narco (sleep)" and "lepsia (seizure)". Gélineau regarded the disease as a neurosis or functional disorder, and his description later became the etymological origin of the disease name.
Around the same time, in 1877, Carl Westphal in Germany independently reported a case of emotion-triggered loss of muscle tone, which was later recognized as the first description of cataplexy. Subsequently, Loewenfeld in 1902 and Kinnier Wilson in 1928 established the terms cataplexy and sleep paralysis, respectively. In the early to mid-20th century, as cases of narcolepsy associated with postencephalitic states and hypothalamic lesions were reported, its neurological basis was gradually recognized.
The decisive turning point in modern narcolepsy research came when the research team of Mignot and Dement at Stanford University established a naturally occurring narcolepsy model in Doberman pinscher dogs in 1984, through which they identified in 1998–2000 that loss of function of the orexin (hypocretin/orexin) system is the key pathogenesis of narcolepsy. In 1998 two research teams independently discovered the hypothalamic secreted peptide orexin/hypocretin, and in 1999–2000 Mignot's team confirmed that CSF orexin-A deficiency is universal in patients with narcolepsy. In 2000, Thannickal et al. demonstrated histopathologically that 85–95% of orexin neurons were lost in autopsied brains of patients with narcolepsy.
As an increase in narcolepsy was reported in some countries after the 2009 H1N1 influenza pandemic and Pandemrix vaccination, the autoimmune triggering mechanism drew further attention. Targeted attack on orexin neurons by CD4+ and CD8+ T cells was subsequently demonstrated, and the molecular mimicry hypothesis was proposed. Recently, selective orexin-2 receptor (OX2R) agonists have been developed, with TAK-861 and others entering phase 3 clinical trials, opening the first treatment paradigm that directly corrects the underlying pathogenesis.
The root cause of type 1 narcolepsy (NT1) is the selective, irreversible destruction of orexin (synonym: hypocretin/HCRT)-secreting neurons located in the lateral hypothalamus. In healthy people there are about 50,000–100,000 of these neurons, but in patients with NT1, 85–95% are lost. As a result, the orexin-A concentration in cerebrospinal fluid (CSF) falls below 110 pg/mL or decreases to undetectable levels.
The mechanism of orexin neuron destruction is strongly presumed to be autoimmune. The evidence is as follows. First, the HLA-DQA1*01:02/DQB1*06:02 haplotype is detected in 98% of patients with NT1, which is consistent with specific HLA molecules presenting self-antigen peptides to T cells in autoimmune mechanisms. Second, direct evidence has been presented that CD4+ and CD8+ T cells specifically target orexin neurons. Third, molecular mimicry studies have identified structural similarity between the influenza hemagglutinin antigen and orexin receptor 2 (OX2R).
As environmental triggers, upper respiratory tract infections, particularly influenza A (H1N1) infection or some H1N1 vaccines (Pandemrix), have been associated with the development of narcolepsy. Cases occurring after beta-hemolytic streptococcal infection have also been reported. In other words, the "two-hit" model, in which a specific environmental antigen triggers an autoimmune response in a genetically susceptible host (HLA-DQB1*06:02 carrier) leading to destruction of orexin neurons, is currently the most widely accepted.
Type 2 narcolepsy (NT2) is a form with normal CSF orexin-A and no cataplexy, and its pathogenesis is less clear. Cases have been reported in which some patients with NT2 develop orexin deficiency over time and evolve into NT1. Symptomatic (secondary) narcolepsy can also be caused by hypothalamic or brainstem lesions (brain tumors, hypothalamic sarcoidosis, multiple sclerosis, paraneoplastic syndromes, etc.).
Type 1 narcolepsy is not a single-gene disorder but a polygenic complex immune disease with a strong HLA association. The HLA-DQB1*06:02 allele is detected in 98% of patients with NT1, which is among the strongest of any known HLA–disease association. HLA-DQA1*01:02 and HLA-DQB1*06:02 are in linkage disequilibrium (LD) and form the DQ1 heterodimer (DQ0102), and this protein is presumed to present orexin peptides to CD4+ T cells.
However, because HLA-DQB1*06:02 is also present at a high frequency of 12–38% in the general population, it alone cannot explain disease onset. That is, this allele is close to a necessary condition but not a sufficient one. Non-HLA genetic factors whose associations have been confirmed in genome-wide association studies (GWAS) include the T-cell receptor alpha (TRA) locus, P2RY11 (purinergic receptor gene), CTSH (cathepsin H), and EIF3G. These genes are associated with regulation of immune function.
Familial occurrence accounts for only about 2–5% of all NT1, and the sibling recurrence risk is estimated at about 1–2%. Thus, despite the strong HLA association, NT1 mostly occurs sporadically. The concordance rate in monozygotic twins is only 25–31%, suggesting the importance of environmental triggers. It was recently reported in PNAS that the HLA-DQB1*03:01 allele modulates the age of onset of NT1 independently of HLA-DQB1*06:02.
In NT2 the HLA-DQB1*06:02 association is much weaker than in NT1 (positivity rate 40–60%). Symptomatic narcolepsy has no HLA association. In genetic counseling, first-degree relatives of patients with NT1 have a 20–40 times higher risk than the general population, but the absolute risk is low (1–2%), so predictive testing should be decided individually according to the clinical situation.
The worldwide prevalence of type 1 narcolepsy varies by region and ethnicity. In Western Europe and the United States it is about 20–50/100,000, and in Japan it is about 160/100,000, the highest in the world. This is attributed to the high frequency of HLA-DQB1*06:02 and different immunogenetic characteristics in the Japanese. It is about 30/100,000 in China and about 15/100,000 in Korea, and markedly lower in sub-Saharan Africa. The number of patients worldwide is estimated at about 3 million.
Age of onset shows a bimodal distribution, with the first peak around age 15 and the second peak around age 35. About 60–70% of all patients develop the disease in their teens to 30s, and first onset after age 50 is rare. Because cataplexy often appears months to years after the onset of excessive daytime sleepiness, actual diagnosis is reported to be delayed by an average of more than 10 years after symptom onset. This is attributed to lack of clinical awareness and misdiagnosis as other sleep disorders or psychiatric disorders.
The male-to-female prevalence ratio is nearly equal in most studies or slightly higher in males (about 1.5:1). Pediatric-onset narcolepsy may present with more atypical symptoms than in adults, and hyperactivity, poor academic performance, and hyperphagia may be preceding signs. Obesity is significantly more common in patients with NT1 than in the general population and is related to orexin deficiency and dysregulation of energy metabolism.
In Korea it is registered and managed under rare disease special code V234 of the Special Copayment Reduction, requiring renewal every 5 years. The socioeconomic burden is large due to decline in social functioning and increased risk of traffic accidents, and safety management is particularly needed in occupations involving driving or operating dangerous machinery.
The core pathophysiology of narcolepsy is that neurons in the lateral hypothalamus that secrete the orexin-A and orexin-B peptides are destroyed by autoimmune attack, causing collapse of the ascending arousal circuits responsible for wakefulness and suppression of REM sleep. Orexin-A projects to a wide range of wake-maintaining nuclei, including the locus coeruleus, dorsal raphe, tuberomammillary nucleus, and brainstem cholinergic neurons, stabilizing wakefulness and suppressing REM sleep.
When orexin neurons are lost, the wake–sleep transition switch (flip-flop switch) becomes unstable, so that there are sudden transitions from wakefulness to sleep or components of REM sleep (loss of muscle tone, dreaming) intrude into wakefulness. Cataplexy is understood as a mechanism in which emotional stimuli (especially laughter, surprise) directly activate the brainstem circuits responsible for the loss of muscle tone in REM sleep, causing loss of muscle tone during wakefulness. This implies that orexin normally inhibits this circuit.
Specific evidence for the autoimmune mechanism includes the following. After CD4+ T cells recognize orexin peptides and cross-reactive viral antigens via HLA-DQ0102, activated CD8+ T cells directly destroy orexin neurons. Molecular mimicry between influenza hemagglutinin and OX2R may cause T-cell cross-activation. Autoantibodies (such as anti-orexin receptor antibodies) have also been reported in some patients, but consistency is lacking.
The metabolic effects of orexin deficiency are also important. Because orexin is involved in energy homeostasis, activation of brown adipose tissue, and regulation of the sympathetic nervous system, orexin deficiency lowers the basal metabolic rate and, through dysregulated appetite control, increases the risk of obesity and type 2 diabetes. Increased leptin resistance and abnormal ghrelin secretion also accompany it. Abnormal thermoregulation and cardiovascular autonomic dysfunction may also appear as systemic consequences of orexin deficiency.
The four cardinal symptoms of type 1 narcolepsy are excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, and hypnagogic/hypnopompic hallucinations. All four occur in only 10–15% of all patients with NT1, and apart from cataplexy, the other three are not specific to NT1.
Excessive daytime sleepiness is the most persistent and disabling symptom, occurring in almost all patients with NT1. Irresistible urges to sleep occur repeatedly, particularly in monotonous and passive situations (listening to lectures, meetings, driving, eating, etc.). A characteristic feature is temporary recovery after a short nap of 10–30 minutes, followed soon by recurrence. Sleep attacks can occur entirely without warning and cause traffic and occupational accidents. Automatic behavior is a phenomenon in which the patient repeats purposeless actions in a semiconscious state, which the patient does not remember.
Cataplexy is the pathognomonic symptom of NT1. It is a sudden loss of muscle tone triggered by strong emotional stimuli such as laughter, jokes, surprise, or anger, and is distinguished from syncope or epilepsy by preserved consciousness. Loss of muscle tone occurs partially or generally, in the facial muscles (jaw dropping, abnormal articulation), neck muscles (head dropping forward), and knee and hip joints (knee buckling, falls). It lasts from a few seconds to under 2 minutes and resolves spontaneously. Early in the disease, partial cataplexy is more common and diagnosis is difficult.
Sleep paralysis is a state of complete inability to make voluntary movements for several minutes on falling asleep or on awakening, with clear consciousness. It is often accompanied by fear and a sense of suffocation. Hypnagogic/hypnopompic hallucinations are vivid, realistic visual, auditory, or somatosensory abnormalities that occur just before or just after sleep onset. Fragmented nighttime sleep is also an important accompanying symptom of NT1, and frequent awakenings, REM sleep behavior disorder (RBD), and periodic limb movement disorder (PLMD) may accompany it.
On clinical examination, direct observation of cataplexy is the most diagnostic objective sign of NT1. Typical findings of cataplexy are facial muscle relaxation (jaw sagging or eyelids drooping), head dropping forward, knee flexion, or a complete fall appearing within seconds of a strong emotional trigger, with consciousness preserved throughout. Experienced clinicians sometimes perform an emotion-provocation test (observing the response after a humorous stimulus) to confirm the findings of cataplexy.
There is no specific focal neurological deficit on neurological examination. However, some patients may show alternating hyperarousal and daytime sleepiness, involuntary ptosis, and episodic abnormal articulation during speech. Overweight or obesity is commonly observed in patients with NT1, reflecting dysregulation of energy metabolism due to orexin deficiency. In children, obesity and precocious puberty may appear as preceding signs.
When an episode of automatic behavior is witnessed, a pattern can be seen in which the patient performs repetitive, inappropriate actions without forming memories. Because sleep paralysis and hypnagogic hallucinations depend on patient report, direct observation during examination is difficult, but vivid hallucination content and experiences of inability to move are confirmed through interview. The instability of the sleep–wake rhythm can be objectified with a sleep diary and actigraphy.
Signs observable during overnight testing include, on PSG, a SOREMP (sleep-onset REM period), reduced sleep efficiency, frequent awakenings, REM sleep-related behaviors, and periodic limb movements (PLM). On the MSLT, the mean sleep latency is 8 minutes or less and SOREMPs are confirmed in 2 or more of 5 nap opportunities.
The first step in screening for narcolepsy is a standardized clinical interview and sleepiness scale assessment. The Epworth Sleepiness Scale (ESS) is a self-assessment of the tendency to doze in 8 everyday situations, each scored 0–3, and a total score above 10 (maximum 24) is the clinical threshold for excessive daytime sleepiness. The mean ESS in patients with NT1 is very high at 17–19 points. The ESS is simple and highly reproducible but has low specificity, so it cannot be used as a stand-alone diagnostic tool.
Complementary self-report tools such as the Stanford Sleepiness Scale (SSS) and sleep disorder questionnaires (SCI, PDSS) are also used. In interviewing for cataplexy, the association with emotional triggers (laughter, jokes), whether consciousness is preserved, duration (usually under 2 minutes), and the recovery process are identified specifically. Severity is quantified using the Cataplexy Severity Scale.
HLA-DQB1*06:02 genotyping has a very high negative predictive value (NPV) and is useful for screening. A negative test virtually excludes a diagnosis of NT1 (sensitivity 98%), so it is used as a cost-effective screening step. However, because 12–38% of the general population carry this allele, a positive result cannot be used as grounds for confirmation, and the diagnosis must be confirmed by polysomnography.
A sleep diary and actigraphy provide an objective record of the sleep–wake pattern over 2 weeks or more and are used to determine the baseline sleep state before testing and to exclude sleep deprivation. Sufficient sleep (≥6 hours/day) must be secured for at least 2 weeks before PSG and MSLT, and antidepressants that suppress REM sleep (TCAs, SNRIs, SSRIs) must be discontinued for at least 2 weeks before testing. It is important to clearly inform patients of these pretest conditions at the screening stage.
The standard diagnostic protocol for NT1 consists of overnight polysomnography (PSG) followed by a Multiple Sleep Latency Test (MSLT) performed the next day. According to the ICSD-3 (International Classification of Sleep Disorders, 3rd edition) and its 2023 revision (ICSD-3-TR) criteria, NT1 is diagnosed when one of the following is met: (1) cataplexy with a CSF orexin-A concentration below 110 pg/mL (or one-third or less of the mean of healthy controls); (2) cataplexy with an MSLT mean sleep latency ≤8 minutes and ≥2 SOREMPs (including a SOREMP on the preceding overnight PSG). The ICSD-3-TR added a criterion allowing diagnosis without the MSLT based solely on a SOREMP during overnight PSG and cataplexy.
The MSLT provides 4–5 nap opportunities of 20 minutes at 2-hour intervals on the day after PSG and records sleep latency and SOREMPs. A mean sleep latency ≤8 minutes and ≥2 SOREMPs are the objective markers of NT1. Sufficient sleep for at least 2 weeks before testing (confirmed by diary/actigraphy) and discontinuation of REM-suppressing drugs are mandatory. PSG evaluates nighttime sleep architecture, the presence of SOREMP, and comorbid sleep disorders (sleep apnea, PLMD).
For CSF orexin-A measurement, CSF obtained by lumbar puncture is analyzed by radioimmunoassay (RIA). Its sensitivity for NT1 is very high at 87% and its specificity above 99%, and it is a decisive diagnostic tool when cataplexy is present but the MSLT is inconclusive, or in patients in whom the MSLT cannot be performed (children, inability to stop medication).
The differential diagnosis includes idiopathic hypersomnia (IH; no SOREMP), delayed sleep–wake phase disorder, hypersomnia associated with depression, residual EDS after treatment of sleep apnea, drug-induced sleepiness, Kleine-Levin syndrome, and symptomatic narcolepsy due to hypothalamic lesions. Brain MRI (to exclude hypothalamic lesions) and basic metabolic tests such as thyroid function and blood glucose are performed in parallel. In children in particular, differentiation from obesity, precocious puberty, and behavioral abnormalities is needed.
Treatment of NT1 requires a multifaceted approach that manages each of the three axes: excessive daytime sleepiness, cataplexy, and fragmented nighttime sleep. The basics of behavioral therapy are maintaining a regular sleep schedule, short scheduled naps (15–20 minutes, 1–3 times a day), avoidance of alcohol and sedatives, and adherence to safe driving guidelines.
First-line drug treatment of excessive daytime sleepiness is modafinil (100–400 mg/day) and armodafinil (75–250 mg/day). They promote wakefulness through inhibition of dopamine reuptake and have a low potential for abuse. Pitolisant is an H3 autoreceptor inverse agonist that activates histaminergic arousal circuits; it is not approved in Korea but is approved in Europe for both EDS and cataplexy in NT1. Solriamfetol is a dopamine–norepinephrine reuptake inhibitor approved by the US FDA. Amphetamines (dextroamphetamine, methylphenidate) are highly effective but are used selectively because of the risk of abuse.
The standard treatment for cataplexy is sodium oxybate (a GHB salt), taken in 2 divided doses at night after going to bed (total 6–9 g/day), which improves consolidation of nighttime sleep and strongly suppresses cataplexy. It is also effective for EDS, making it the only drug that can control all three symptoms of NT1 as a single agent. Mixed salts oxybate (LXB) is a formulation with reduced sodium content. Antidepressants (venlafaxine, fluoxetine, clomipramine) are effective for cataplexy, sleep paralysis, and hallucinations through REM suppression, but caution is needed for rebound cataplexy (cataplexy status) on abrupt discontinuation.
The most notable new treatment under development is selective orexin-2 receptor (OX2R) agonists. TAK-861 significantly improved EDS, cataplexy, and MSLT results in a phase 2 clinical trial and has entered phase 3. This is the first strategy to directly correct the underlying pathogenesis of orexin deficiency and, if approved, is expected to shift the treatment paradigm for NT1. Attempts at immunotherapy (IVIg, plasma exchange) have a theoretical rationale in the active autoimmune phase early in the disease, but evidence is insufficient and they are not currently standard treatment.
NT1 is not a fatal disease but a lifelong chronic neurological disorder, and spontaneous remission almost never occurs. Cataplexy tends to decrease in frequency after decades in some patients, but excessive daytime sleepiness persists without treatment. With appropriate drug treatment combined with behavioral management, most patients can maintain occupational functioning, social life, and studies.
When untreated or inadequately treated, the main complications are reduced quality of life, increased risk of traffic and occupational accidents, depression, and social isolation. Comorbid depression is high in patients with NT1 at 25–50%, attributable both to orexin deficiency itself and to the psychological burden of chronic illness. Anxiety disorders and attention-deficit/hyperactivity disorder (ADHD)-like symptoms are also common.
Reported metabolic complications include obesity (elevated body mass index), insulin resistance, and an increased risk of type 2 diabetes. Cardiovascular autonomic dysfunction (reduced heart rate variability) is also observed in NT1. Driving safety is a major clinical management issue, and in Korea as well, assessment of fitness to drive is needed for patients with narcolepsy whose excessive daytime sleepiness is not controlled. Driving is permitted in patients with a sufficient response to drug treatment, but the decision must always be made after consulting a clinician.
The long-term effects of metabolic and immune abnormalities due to orexin deficiency are currently being followed in prospective cohort studies. If new treatments (OX2R agonists) are introduced, the prognosis is expected to improve greatly. Even with current standard treatment, most patients can maintain near-normal functioning, so early diagnosis and active treatment are key to determining prognosis.
Prevention of the cause of NT1 (prevention of disease onset itself) is currently impossible. Immunoprophylactic strategies to protect orexin neurons before the onset of autoimmunity have been proposed theoretically but have not reached clinical application. However, from the perspective of secondary and tertiary prevention, morbidity can be minimized through early diagnosis, appropriate treatment, safety management, and preservation of quality of life.
Adherence to sleep hygiene is the foundation of symptom relief. Recommended measures include maintaining regular bedtimes and wake times, securing sufficient nighttime sleep (7–9 hours), taking scheduled naps (1–3 times a day, within 15–20 minutes), and avoiding alcohol, caffeine, and sedative-hypnotics. Completely avoiding emotion-provoking situations is not realistic, but safety measures in situations where cataplexy poses a risk (working at heights, while driving, cooking) are essential.
Regarding vaccination, cases of increased narcolepsy have been reported in some countries after Pandemrix vaccination in 2009–2011. Since then, the hypothesis that vaccine components (particularly the AS03 adjuvant + H1N1 hemagglutinin antigen) can trigger autoimmunity through molecular mimicry in HLA-DQB1*06:02 carriers has been studied. Because the vaccine is no longer in use, practical preventive application is limited, but immunogenetic safety assessment may be needed when similar vaccines are developed in the future.
For management of high-risk groups (HLA-DQB1*06:02 carriers, those with a family history), it is important to educate them to seek specialist evaluation immediately when early symptoms such as excessive daytime sleepiness or cataplexy appear. Starting appropriate treatment through early diagnosis can minimize loss of occupational and social functioning. Education of families and caregivers of patients with narcolepsy is also part of secondary prevention.